company background image
PROM

Promore Pharma OM:PROMO Stock Report

Last Price

kr1.06

Market Cap

kr67.4m

7D

9.5%

1Y

-35.9%

Updated

05 Oct, 2022

Data

Company Financials
PROMO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PROMO Stock Overview

Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally.

Promore Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Promore Pharma
Historical stock prices
Current Share Pricekr1.06
52 Week Highkr2.00
52 Week Lowkr0.90
Beta0.52
1 Month Change-3.64%
3 Month Change-6.19%
1 Year Change-35.91%
3 Year Change-77.92%
5 Year Change-92.98%
Change since IPO-92.35%

Recent News & Updates

Shareholder Returns

PROMOSE BiotechsSE Market
7D9.5%17.0%5.1%
1Y-35.9%-28.8%-24.4%

Return vs Industry: PROMO underperformed the Swedish Biotechs industry which returned -28.8% over the past year.

Return vs Market: PROMO underperformed the Swedish Market which returned -24.4% over the past year.

Price Volatility

Is PROMO's price volatile compared to industry and market?
PROMO volatility
PROMO Average Weekly Movement11.3%
Biotechs Industry Average Movement8.5%
Market Average Movement7.0%
10% most volatile stocks in SE Market11.5%
10% least volatile stocks in SE Market4.3%

Stable Share Price: PROMO is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: PROMO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20021Jonas Ekblomhttps://www.promorepharma.com

Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes.

Promore Pharma AB (publ) Fundamentals Summary

How do Promore Pharma's earnings and revenue compare to its market cap?
PROMO fundamental statistics
Market Capkr67.39m
Earnings (TTM)-kr26.31m
Revenue (TTM)kr481.00k

133.8x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PROMO income statement (TTM)
Revenuekr481.00k
Cost of Revenuekr15.18m
Gross Profit-kr14.70m
Other Expenseskr11.61m
Earnings-kr26.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 29, 2022

Earnings per share (EPS)-0.43
Gross Margin-3,056.34%
Net Profit Margin-5,470.48%
Debt/Equity Ratio2.7%

How did PROMO perform over the long term?

See historical performance and comparison